|
1
|
Tian H, Xu W, Wen L, Song T, Tian Y, Tang L, Guo N, Chen Q, Wang H, Zhang K, Zhang X, Peng Y. Relationship between CCL2 gene 2518A/G (rs1024611) polymorphism and age-related macular degeneration susceptibility: meta-analysis and trial sequential analysis. Int Ophthalmol 2024; 44:348. [PMID: 39141020 DOI: 10.1007/s10792-024-03266-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Accepted: 07/29/2024] [Indexed: 08/15/2024]
Abstract
PURPOSE This study aimed to investigate the association between the CC-cytokine ligand-2 (CCL2) 2518A/G (rs1024611) single nucleotide polymorphism (SNP) and susceptibility to age-related macular degeneration (AMD). METHODS PubMed, Embase, Web of Science, and other databases were searched for articles published before August 24, 2023. After searching, data extraction, and quality assessment, meta-analysis and trial sequential analysis were conducted using RevMan 5.4, Stata 17.0, and TSA 0.9.5.10 Beta software. Combined OR, P values, and 95% confidence intervals (CIs) were calculated. Sensitivity analysis, subgroup analysis and publication bias assessment were also performed. RESULTS Six articles, comprising 1186 cases and 1124 controls, were included. No significant statistical difference was found in six main outcomes. However, due to observed heterogeneity and high sensitivity, subgroup analysis was performed, revealing statistically significant differences across different regions. No significant publication bias was observed. Trial sequential analysis suggested the need for additional follow-up case-control studies to further validate the findings. CONCLUSION The CCL2 gene 2518A/G (rs1024611) polymorphism is associated with AMD susceptibility. Among Caucasian populations in West Asia and Europe, the G allele is protective against AMD, whereas in East and South Asia, it poses a risk factor.
Collapse
Affiliation(s)
- Haokun Tian
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Weikai Xu
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Lequan Wen
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Tiangang Song
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Ye Tian
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Lirui Tang
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Nan Guo
- The Third Affiliated Hospital of Nanchang University, Nanchang, China
- The Third Clinical Medical College, Nanchang University, Nanchang, China
| | - Qianxi Chen
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Haoran Wang
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Kaiyuan Zhang
- College of Public Health, Zhengzhou University, Zhengzhou, China
| | - Xinyuan Zhang
- Joint Programme of Nanchang University and Queen Mary University of London, Nanchang University, Nanchang, China
- Queen Mary School, Nanchang University, Nanchang, China
- Nanchang Joint Programme, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK
| | - Yu Peng
- Department of Ophthalmology, First Affiliated Hospital of Nanchang University, Nanchang, China.
| |
Collapse
|
|
2
|
Petreski T, Piko N, Ekart R, Hojs R, Bevc S. Review on Inflammation Markers in Chronic Kidney Disease. Biomedicines 2021; 9:182. [PMID: 33670423 PMCID: PMC7917900 DOI: 10.3390/biomedicines9020182] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 02/04/2021] [Accepted: 02/09/2021] [Indexed: 02/07/2023] Open
Abstract
Chronic kidney disease (CKD) is one of the major health problems of the modern age. It represents an important public health challenge with an ever-lasting rising prevalence, which reached almost 700 million by the year 2017. Therefore, it is very important to identify patients at risk for CKD development and discover risk factors that cause the progression of the disease. Several studies have tackled this conundrum in recent years, novel markers have been identified, and new insights into the pathogenesis of CKD have been gained. This review summarizes the evidence on markers of inflammation and their role in the development and progression of CKD. It will focus primarily on cytokines, chemokines, and cell adhesion molecules. Nevertheless, further large, multicenter studies are needed to establish the role of these markers and confirm possible treatment options in everyday clinical practice.
Collapse
Affiliation(s)
- Tadej Petreski
- Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; (T.P.); (N.P.); (R.H.)
- Department of Internal Medicine and Department of Pharmacology, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia
| | - Nejc Piko
- Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; (T.P.); (N.P.); (R.H.)
- Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia;
| | - Robert Ekart
- Department of Internal Medicine and Department of Pharmacology, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia
- Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia;
| | - Radovan Hojs
- Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; (T.P.); (N.P.); (R.H.)
- Department of Internal Medicine and Department of Pharmacology, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia
| | - Sebastjan Bevc
- Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; (T.P.); (N.P.); (R.H.)
- Department of Internal Medicine and Department of Pharmacology, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia
| |
Collapse
|
|
3
|
de Oliveira Junior WV, Silva APF, de Figueiredo RC, Gomes KB, Simões E Silva AC, Dusse LMS, Rios DRA. Association between dyslipidemia and CCL2 in patients undergoing hemodialysis. Cytokine 2019; 125:154858. [PMID: 31557637 DOI: 10.1016/j.cyto.2019.154858] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 08/29/2019] [Accepted: 09/12/2019] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Hemodialysis (HD) is associated with high risk for cardiovascular diseases including acute myocardial infarction, stroke and congestive heart failure. C-C Motif Chemokine Ligand 2 (CCL2), also known monocyte chemotactic protein-1 (MCP-1) can be produced by a variety of cells, reaching increased levels in dyslipidemic chronic kidney disease (CKD) patients undergoing HD treatment. The main of this study was to evaluate the association between of CCL2 plasma levels and dyslipidemia in CKD patients undergoing HD. METHODS A cross-sectional study enrolled 160 Brazilian HD patients. CCL2 plasma levels were measured by capture ELISA. The association between CCL2 levels and dyslipidemia was investigated using linear regression, adjusted for classic and non-classical CVD risk factors. RESULTS A significant association was observed between CCL2 levels and dyslipidemia (P = 0.029), even after adjustment for possible confounding variables, such as age, gender, body mass index, diabetes mellitus, HD time, urea pre-hemodialysis and interdialytic weight gain (P = 0.045). CONCLUSION Our findings show that CCL2 levels are associated with dyslipidemia, which suggests a role of this cytokine in the pathogenesis of cardiovascular disease in HD patients. A better understanding of this pathogenesis could contribute to the discovery of new therapeutic targets that would reduce cardiovascular complications in these patients.
Collapse
Affiliation(s)
| | | | | | - Karina Braga Gomes
- Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia - Universidade Federal de Minas Gerais, Brazil
| | - Ana Cristina Simões E Silva
- Departamento de Pediatria, Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina - Universidade Federal de Minas Gerais, Brazil
| | - Luci Maria Sant'Ana Dusse
- Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia - Universidade Federal de Minas Gerais, Brazil
| | | |
Collapse
|